The shareholders in CellaVision AB are hereby summoned to the Annual General Meeting, to be held on May 5, 2017 at 15.00 at CellaVision AB, Mobilvägen 12, Ideon in Lund, Sweden.
The complete notice is available in Swedish only.
For more information, please contact:
Zlatko Rihter, CEO, CellaVision AB
Phone: +46 733 62 11 06 | E-mail: zlatko.rihter@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2016 sales were SEK 265 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has market support offices in the USA, Canada, Japan, China, Souh Korea, Dubai, Australia and France. The share is listed on the Nasdaq Stockholm, Small Cap list. Read more at www.cellavision.com
